Generic Drug
Product Images NDC 72994-002

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Generic Drug (NDC 72994-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ningbo Shouzheng Medicinal Research Co., Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

8680f005 1ff4 80f4 E053 2a91aa0af6a4

This is a 60 tablet container of Memantine Hydrochloride, which is used for the treatment of Alzheimer's disease. Each tablet contains 10mg of memantine hydrochloride USP. The package insert should be reviewed for dosing and other prescribing information. The manufacturer is Ningbo Shuangcheng Pharmaceutical Co., Ltd and it is distributed by Ningbo Shouzheng Medicinal Research Co., Ltd. It should be stored at room temperature in a tightly closed container and kept away from children.*

FDA Label Image

8680f005 1ff5 80f4 E053 2a91aa0af6a4

This is a description of a prescription drug named Memantine Hydrochloride Tablets, USP. The medicine comes in a pack of 60 tablets, and each tablet contains 5mg of the active ingredient. The drug is meant for adult use only and should be kept out of reach of children. It must be dispensed in a tightly sealed container and stored at a temperature of 25°C. The packaging includes a two-dimensional barcode, and the full prescribing information can be obtained from the package insert. The product is manufactured by Ningbo Shuangcheng Pharmaceutical Co., Ltd in China, for Ningbo Shouzheng Medicinal Research Co., Ltd.*

FDA Label Image

Draft Container Label 10mg60ct (Draft Container Label 10mg60ct)

Memantine Hydrochloride Tablets, USP are prescription drugs containing 10mg of memantine hydrochloride USP. The tablets should be kept out of reach of children and stored in a tight container at 25°C (77°F), with some excursions permitted. The package insert contains full prescribing information and dosing instructions. The drugs are manufactured by Ningbo Shuangcheng Pharmaceuticals in Zhejiang Province, China, for Ningbo Shouzheng Medicinal Research Co., Ltd.*

FDA Label Image

Draft Container Label 5mg60ct (Draft Container Label 5mg60ct)

This is a description of a medication called Memantine Hydrochloride available in the form of USP tablets containing 5 mg of the mentioned substance. It is an Rx only drug that comes in a tightly closed container and 60 tablets in quantity. The package insert for dosing and complete prescribing information is available. The manufacturing company is Ningbo Shouzheng Medicinal Research Co., Ltd, and it's distributed by Ningbo Shheng Pharmaceuticals Ct in China. It has to be kept away from children and stored under controlled room temperature as mentioned in the USP. No other relevant information is available.*

FDA Label Image

Figure 1: Time Course Of The Change From Baseline Inadcs-adl Score For Patients Completing 28 Weeks Of Treatment. (Figure1)

FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Figure2)

This text appears to be a chart or graph with labels indicating the cumulative percentage of patients and the change from baseline on the ADCSADL scale for three potential treatments: placebo, Memarine, and Hol. The chart may provide some useful data or information, but without a visual representation it is difficult to say more.*

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Sib Score For Patients Completing 28 Weeks Of Treatment. (Figure3)

This appears to be a chart displaying data related to a treatment, possibly for a clinical study. The x-axis shows the number of weeks of treatment and the y-axis shows the mean change from baseline with SEM. Two treatments are being compared: Flacebo and Hermariine HOI. However, the information provided is not sufficient to draw any further conclusions or provide a more detailed description.*

FDA Label Image

Figure 4: Cumulative Percentage Of Patients Completing 28 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Figure4)

FDA Label Image

Figure 5: Time Course Of The Change From Baseline In Adcs-adl Score For Patients Completing 24 Weeks Of Treatment. (Figure5)

FDA Label Image

Figure 6: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adcs-adl Scores. (Figure6)

The text shows a graph indicating the cumulative percentage of patients on two different medications (Plcebol and Donepezil) based on the ADCS-ADL Change from Baseline, with the x-axis showing the change percentage and the y-axis showing the percentage of patients.*

FDA Label Image

Figure 7: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Figure7)

FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Figure8)

FDA Label Image

Structural Formula (Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.